In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or ...

Traditional risk factors and prior CV disease aren’t the whole story when it comes to increased rates of all-cause mortality in patients with NVAF, say these researchers. Here’s what ...

Expert Rev Cardiovasc Ther. 2012;10(4):433-439. Another important trial that needs discussion is the ROCKET AF trial. ROCKET AF studied 14,264 patients with nonvalvular AF and compared the Factor ...

Data from a Japanese registry may be useful for characterizing frailty among older patients with nonvalvular atrial fibrillation (NVAF), possibly opening the door to better treatment decisions and ...

Cite this: Anticoagulants for Nonvalvular Atrial Fibrillation (NVAF) -- Drug Review - Medscape - Feb 07, 2003. Abstract and Introduction Methodologic Problems in the Randomized Controlled Trials ...

Background: Too few patients with nonvalvular atrial fibrillation (NVAF) receive appropriate antithrombotic therapy. We tested the short-term (primary outcome) and long-term (secondary outcome) effect ...

Nonvalvular Atrial Fibrillation and Risk of Stroke Rajat Deo, MD, assistant professor of medicine at the University of Pennsylvania Atrial fibrillation is a common arrhythmia.

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure ...

Background: Nonvalvular atrial fibrillation (AF) is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment.